New medications for treatment of obesity: metabolic and cardiovascular effects.

[1]  A. Astrup,et al.  Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight‐loss outcomes , 2014, Obesity.

[2]  V. Gebski,et al.  Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease , 2014, International Journal of Obesity.

[3]  Alan D. Lopez,et al.  Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2014, The Lancet.

[4]  P. Whincup,et al.  Lifelong patterns of BMI and cardiovascular phenotype in individuals aged 60-64 years in the 1946 British birth cohort study: an epidemiological study. , 2014, The lancet. Diabetes & endocrinology.

[5]  R. Seeley,et al.  Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. , 2014, The Journal of clinical investigation.

[6]  G. Roglić,et al.  Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. , 2014, The lancet. Diabetes & endocrinology.

[7]  A. Astrup,et al.  Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity , 2014, Journal of hypertension.

[8]  Crystal L. Hoyt,et al.  “Obesity Is a Disease” , 2014, Psychological science.

[9]  C. Hampp,et al.  Use of Prescription Antiobesity Drugs in the United States , 2013, Pharmacotherapy.

[10]  F. Greenway,et al.  Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes , 2013, Diabetes Care.

[11]  M. Lean,et al.  The disproportionate economic burden associated with severe and complicated obesity: a systematic review , 2013, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[12]  L. Aronne,et al.  Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study , 2013, International Journal of Obesity.

[13]  B. Zinman,et al.  Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. , 2013, American heart journal.

[14]  Deepak L. Bhatt,et al.  Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials , 2013, BMJ.

[15]  Arya M. Sharma,et al.  Weight Recidivism Post-Bariatric Surgery: A Systematic Review , 2013, Obesity Surgery.

[16]  A. Astrup,et al.  Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults , 2013, International Journal of Obesity.

[17]  G. Koch,et al.  Echocardiographic Assessment of Cardiac Valvular Regurgitation With Lorcaserin From Analysis of 3 Phase 3 Clinical Trials , 2013, Circulation. Cardiovascular imaging.

[18]  C. Lamendola,et al.  Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes , 2013, Diabetes Care.

[19]  D. Cohen.  Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? , 2013, BMJ.

[20]  A. Astrup,et al.  Obesity in Europe – does anybody care? , 2013, Expert opinion on pharmacotherapy.

[21]  R. Elashoff,et al.  A Critical Analysis of the Clinical Use of Incretin-Based Therapies , 2013, Diabetes Care.

[22]  A. Wong,et al.  Efficacy and safety of lorcaserin in obese adults: a meta‐analysis of 1‐year randomized controlled trials (RCTs) and narrative review on short‐term RCTs , 2013, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[23]  G. Bray,et al.  Pharmacologic Treatment Options for Obesity: What Is Old Is New Again , 2013, Current Hypertension Reports.

[24]  B. Sommer,et al.  Therapeutic Advances in Neurological Disorders , 2013 .

[25]  Daniel B. Jones,et al.  Expectations for weight loss and willingness to accept risk among patients seeking weight loss surgery. , 2013, JAMA surgery.

[26]  Deepak L. Bhatt,et al.  Metabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes , 2013, Diabetes Care.

[27]  Dennis D. Kim,et al.  A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II) , 2013, Obesity.

[28]  M. Lean,et al.  Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity. , 2013, The British journal of general practice : the journal of the Royal College of General Practitioners.

[29]  J. Holst,et al.  Incretin hormones and the satiation signal , 2013, International Journal of Obesity.

[30]  Alan D. Lopez,et al.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[31]  Andrew Lloyd,et al.  Willingness to Pay for Obesity Pharmacotherapy , 2012, Obesity.

[32]  M. Tschöp,et al.  Anti-obesity drugs: past, present and future , 2012, Disease Models & Mechanisms.

[33]  E. Aasheim,et al.  Effect of bypassing the proximal gut on gut hormones involved with glycemic control and weight loss. , 2012, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[34]  J. Holst,et al.  Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. , 2012, American journal of physiology. Endocrinology and metabolism.

[35]  P. O'Neil,et al.  Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study , 2012, Obesity.

[36]  L J Gray,et al.  Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta‐analysis , 2012, Diabetes, obesity & metabolism.

[37]  P. O’Brien,et al.  Predictors of Attrition in Bariatric Aftercare: A Systematic Review of the Literature , 2012, Obesity Surgery.

[38]  C. Torp‐Pedersen,et al.  Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial , 2012, Diabetes, obesity & metabolism.

[39]  E. Colman.  Food and Drug Administration's Obesity Drug Guidance Document: A Short History , 2012, Circulation.

[40]  J. Holst,et al.  Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass , 2012, Diabetologia.

[41]  D. Drucker,et al.  Cardiovascular biology of the incretin system. , 2012, Endocrine reviews.

[42]  B. Geloneze,et al.  Comparison of Metabolic Effects of Surgical-Induced Massive Weight Loss in Patients with Long-Term Remission Versus Non-remission of Type 2 Diabetes , 2012, Obesity Surgery.

[43]  M. Christensen,et al.  Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials , 2012, BMJ : British Medical Journal.

[44]  C. Bouchard,et al.  Bariatric surgery and long-term cardiovascular events. , 2012, JAMA.

[45]  K. Gadde,et al.  Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2011, The American journal of clinical nutrition.

[46]  K. Gadde,et al.  Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) , 2011, Obesity.

[47]  E. Bullmore,et al.  Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs , 2011, CNS neuroscience & therapeutics.

[48]  Daniel B. Jones,et al.  First Report from the American College of Surgeons Bariatric Surgery Center Network: Laparoscopic Sleeve Gastrectomy has Morbidity and Effectiveness Positioned Between the Band and the Bypass , 2011, Annals of surgery.

[49]  A. Astrup,et al.  Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide , 2011, International Journal of Obesity.

[50]  N. Weissman,et al.  A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. , 2011, The Journal of clinical endocrinology and metabolism.

[51]  K. Gadde,et al.  Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[52]  M. Davidson,et al.  WEIGHT LOSS AND CARDIOVASCULAR RISK REDUCTION OVER 2 YEARS WITH CONTROLLED-RELEASE PHENTERMINE-TOPIRAMATE , 2011 .

[53]  C. Rock,et al.  Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial , 2011, Obesity.

[54]  M. Zdravkovic,et al.  Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase , 2010, Drug Metabolism and Disposition.

[55]  Arya M. Sharma,et al.  Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. , 2010, The New England journal of medicine.

[56]  F. Greenway,et al.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2010, The Lancet.

[57]  N. Weissman,et al.  Multicenter, placebo-controlled trial of lorcaserin for weight management. , 2010, The New England journal of medicine.

[58]  I. Brown,et al.  Patients’ experiences of prescribed anti-obesity drugs and perceptions of support from primary care: a qualitative study , 2010, Primary Health Care Research & Development.

[59]  N. Abumrad,et al.  The Importance of Caloric Restriction in the Early Improvements in Insulin Sensitivity After Roux-en-Y Gastric Bypass Surgery , 2010, Diabetes Care.

[60]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[61]  D. Drucker,et al.  Incretin-based therapies for type 2 diabetes mellitus , 2009, Nature Reviews Endocrinology.

[62]  G. Brandacher,et al.  Vagal Nerve Dissection During Pouch Formation in Laparoscopic Roux-Y-Gastric Bypass for Technical Simplification: Does it Matter? , 2009, Obesity surgery.

[63]  R. Collins,et al.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, Lancet.

[64]  Christine I. Turenius,et al.  GABAA receptors in the lateral hypothalamus as mediators of satiety and body weight regulation , 2009, Brain Research.

[65]  S. Salinari,et al.  First-Phase Insulin Secretion Restoration and Differential Response to Glucose Load Depending on the Route of Administration in Type 2 Diabetic Subjects After Bariatric Surgery , 2009, Diabetes Care.

[66]  K. Gadde,et al.  Rational Design of a Combination Medication for the Treatment of Obesity , 2009, Obesity.

[67]  Claude Bouchard,et al.  Effects of bariatric surgery on mortality in Swedish obese subjects. , 2007, The New England journal of medicine.

[68]  A. Patriti,et al.  How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced Proglucagon gene expression and L-cell number. , 2007, Surgery.

[69]  T. Wadden,et al.  The role of patients' expectations and goals in the behavioral and pharmacological treatment of obesity , 2007, International Journal of Obesity.

[70]  J. Douketis,et al.  2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary] , 2007, Canadian Medical Association Journal.

[71]  K. Gadde,et al.  Bupropion Treatment of Olanzapine-Associated Weight Gain: An Open-Label, Prospective Trial , 2006, Journal of clinical psychopharmacology.

[72]  J. Douketis,et al.  Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice , 2005, International Journal of Obesity.

[73]  Thomas Wadden,et al.  Systematic Review: An Evaluation of Major Commercial Weight Loss Programs in the United States , 2005, Annals of Internal Medicine.

[74]  S. Toubro,et al.  Topiramate: a new potential pharmacological treatment for obesity. , 2004, Obesity research.

[75]  A. Astrup,et al.  Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. , 2004, Obesity research.

[76]  F. Lebargy,et al.  Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. , 2004, Addiction.

[77]  K. Gadde,et al.  Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. , 2002, Obesity research.

[78]  W. Saris.  Very-low-calorie diets and sustained weight loss. , 2001, Obesity research.

[79]  James W. Anderson,et al.  Long-term weight-loss maintenance: a meta-analysis of US studies. , 2001, The American journal of clinical nutrition.

[80]  N. Finer.  Low-calorie diets and sustained weight loss. , 2001, Obesity research.

[81]  M. F. Sugrue.  Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors , 2000, Progress in Retinal and Eye Research.

[82]  J. C. Winter,et al.  The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs III: the mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion , 1995, Psychopharmacology.

[83]  A. Damasio,et al.  Effect of naltrexone on senile dementia of the Alzheimer type. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[84]  S. Yanovski,et al.  Long-term drug treatment for obesity: a systematic and clinical review. , 2014, JAMA.

[85]  G. Bray,et al.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. , 2013, The New England journal of medicine.

[86]  B. Kulseng,et al.  Eating Behavior and Glucagon-Like Peptide-1-Producing Cells in Interposed Ileum and Pancreatic Islets in Rats Subjected to Ileal Interposition Associated with Sleeve Gastrectomy , 2012, Obesity Surgery.

[87]  J. Shepherd,et al.  The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. , 2011, Health technology assessment.

[88]  B. Drolet,et al.  Impact of Weight-Loss Medications on the Cardiovascular System , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[89]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[90]  K. Rice,et al.  Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin , 2001, Synapse.

[91]  P. O'Neil,et al.  A controlled trial of naltrexone in obese humans. , 1985, International journal of obesity.